Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial

Cangrelor, a potent intravenous, reversible, platelet P2Y12 inhibitor, was recently approved by both the U.S. Food and Drug Administration and the European Medicines Agency as an adjunct for percutaneous coronary intervention. The approval was based on CHAMPION PHOENIX (A Clinical Trial Comparing